Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genvor IncGNVR · Entity 7842 | Director · Chief Research Officer | May 08, 2025 | December 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genvor Inc
Report date May 08, 2025 · Filed December 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 524,000 |
Ending reported balance
After 2025-12-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-08 · Grant · Acquired 400,000 · Balance 400,000 F1: Conversion of $100,000 in accrued payables due to Dr. Jaynes at $0.25/share. Row 2 · 2025-12-02 · Grant · Acquired 124,000 · Balance 524,000 F2: Conversion of $186,000 in accrued payables due to Dr. Jaynes at $1.50/share. |
Filing footnotes · ownership attribution and instrument terms
F1: Conversion of $100,000 in accrued payables due to Dr. Jaynes at $0.25/share.
F2: Conversion of $186,000 in accrued payables due to Dr. Jaynes at $1.50/share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2025 Filed Dec 5, 2025 21:06 UTC | Genvor Inc GNVR · Entity 7842 | GrantCommon Stock | 124,000 | $1.50 | $186,000.00 |
DisclosureSEC source: 0001903596-25-000569 · ownership.xml · nonDerivative · entry 2 Jaynes Jessee M · CIK 0002075345 · Director · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,000 F2 · price: Conversion of $186,000 in accrued payables due to Dr. Jaynes at $1.50/share. Read SEC document |
| May 08, 2025 Filed Dec 5, 2025 21:06 UTC | Genvor Inc GNVR · Entity 7842 | GrantCommon Stock | 400,000 | $0.25 | $100,000.00 |
DisclosureSEC source: 0001903596-25-000569 · ownership.xml · nonDerivative · entry 1 Jaynes Jessee M · CIK 0002075345 · Director · Chief Research Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 F1 · price: Conversion of $100,000 in accrued payables due to Dr. Jaynes at $0.25/share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.